Stockscreener 앱 받기
3.73
3.37%
-0.13
시간 외 거래:
3.80
0.07
+1.88%
전일 마감가:
$3.86
열려 있는:
$3.82
하루 거래량:
186.35K
Relative Volume:
0.46
시가총액:
$36.33M
수익:
$21.73M
순이익/손실:
$-91.17M
주가수익비율:
-5.0405
EPS:
-0.74
순현금흐름:
$-286.43M
1주 성능:
-9.25%
1개월 성능:
-48.55%
6개월 성능:
-69.21%
1년 성능:
-86.58%
1일 변동 폭
$3.67
$3.85
1주일 범위
$3.67
$4.14
52주 변동 폭
$3.56
$30.90
Bluebird Bio Inc Stock (BLUE) Company Profile
명칭
Bluebird Bio Inc
전화
339-499-9300
주소
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
3.73 | 36.33M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-11-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-11-15 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-08-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-12-11 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2023-12-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-19 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-28 | 개시 | JP Morgan | Overweight |
| 2023-03-07 | 개시 | Robert W. Baird | Outperform |
| 2022-08-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-07 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 재확인 | Barclays | Equal Weight |
| 2021-11-08 | 재확인 | Canaccord Genuity | Hold |
| 2021-11-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-11-08 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 재확인 | Wedbush | Neutral |
| 2021-11-08 | 재확인 | Wells Fargo | Equal Weight |
| 2021-08-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 재개 | William Blair | Mkt Perform |
| 2021-08-09 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-03-10 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-02-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-02-16 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-11-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 개시 | Mizuho | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-27 | 업그레이드 | Stifel | Hold → Buy |
| 2020-02-19 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 재개 | BofA/Merrill | Buy |
| 2020-02-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-10-01 | 개시 | Stifel | Hold |
| 2019-08-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | 업그레이드 | Maxim Group | Hold → Buy |
모두보기
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace
bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - Defense World
Stem Cell Therapy Market Growth | Trends, Size & Forecast - openPR
BMS to Acquire Abecma Partner 2seventy bio for $286M - Genetic Engineering & Biotechnology News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga
Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals
Rhumbline Advisers Cuts Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Bluebird bio’s chief medical officer Richard Colvin sells $2,288 in stock - Investing.com Australia
Bluebird bio’s chief commercial officer sells $1,959 in stock - Investing.com
Bluebird bio’s chief commercial officer sells $1,959 in stock By Investing.com - Investing.com Australia
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - Defense World
bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - ACCESS Newswire
Levi & Korsinsky Reminds bluebird bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Lost Money on bluebird bio, Inc. (BLUE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Multiple Myeloma Treatment Market Size Report 2034 | - openPR
Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Turbulence at the FDA & bluebird Bio’s sale - STAT
bluebird bio stock slides for second day on buyout news - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Drug and Gene Delivery Devices Market Growth in Future Scope - openPR
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire
BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Contrasting bluebird bio (NASDAQ:BLUE) and Valneva (NASDAQ:VALN) - Defense World
Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle
bluebird bio (NASDAQ:BLUE) Given New $5.00 Price Target at Wells Fargo & Company - Defense World
Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha
JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com
JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq
Troubled gene therapy player bluebird sold for a song - pharmaphorum
Amneal pharma, Aramark, Bluebird Bio - TradingView
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News
bluebird bio announces take-private deal with Carlyle and SK Capital - MSN
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN
Private equity firms rescue bluebird bio out of its misery - The Pharma Letter
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN
Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Bluebird Bio Inc (BLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):